Highlights • Next generation sequencing (NGS) was performed on patients on PI monotherapy. • It revealed previously unidentified minority variant protease mutations in 3 samples. • These mutations do not predict clinically important phenotypic resistance. Background The PIVOT trial examined whether patients with suppressed viral load on combination antiretroviral therapy could be safely switched long-term to ritonavir-boosted protease inhibitor (PI) monotherapy. The main trial publication reported that only one of 296 patients allocated to PI monotherapy experienced a loss of drug options due to protease mutations (identified by local Sanger sequencing resistance tests) likely selected by study drug. Objectives To assess if we had missed low frequency mutations, using a more sensitive methodology. Study design We performed next generation sequencing (NGS) on all available frozen plasma samples with VL >1000 copies/ml from patients who were randomised to PI monotherapy. Assays were performed at Public Health England laboratories using a previously described method. Median coverage depth was 76,000 and the threshold for detection of minority variants was 2%. Drug susceptibility was predicted using the Stanford HIVdb algorithm. Results 17 of 26 potential samples, all from different patients, were identified and successfully tested. The median viral load was 6780 copies/ml and the median time since randomisation was 43 weeks. NGS revealed previously unidentified minority variant protease mutations (G73D, I54T, L89V) in three samples, at frequencies ranging between 2% and 10%. None of these mutations predicted intermediate or high level resistance, the trial primary outcome. Discussion This report adds to the body of evidence that ritonavir-boosted PI monotherapy, when used as a switch strategy with prompt detection of viral load rebound and early re-introduction of combination therapy, rarely leads to the development of clinically important protease resistance mutations.
【저자키워드】 HIV, NGS, Protease inhibitor, resistance, 【초록키워드】 Mutation, Trial, randomised, susceptibility, Sequencing, mutations, variant, Ritonavir, combination therapy, Local, drug, protease, Laboratory, Coverage, Viral, Sanger sequencing, Viral load, Algorithm, Antiretroviral therapy, Patient, Study design, next generation sequencing, methodology, threshold, monotherapy, patients, predict, Evidence, Combination, Frequency, leads, low frequency, frozen plasma, Primary outcome, frequencies, randomisation, median time, study drug, Median viral load, Highlights, phenotypic, Public Health England, drug susceptibility, objective, Stanford, plasma sample, Result, selected, tested, described, predicted, performed, examined, reported, clinically, was performed, suppressed, the median, 【제목키워드】 Trial, Sequencing, HIV-1,